Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia (scientific article published on 28 May 2013)

The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults

Q34242471

Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia

Q35855167

Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection

Q36168439

Advances in psychotropic formulations

Q36470274

Outpatient antipsychotic treatment and inpatient costs of schizophrenia

Q37076234

Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials

Q37451403

First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies

Q37625683

Cost of disorders of the brain in Europe 2010.

Q37933664

Efficacy and safety of long acting injectable atypical antipsychotics: a review

Q38076206

Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics

Q38077554

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia

Q38364268

Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study

Q38469670

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain

Q40050506

Cost of relapse in schizophrenia

Q41008145

Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis

Q42936504

Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia

Q43149273

Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System

Q43264511

Long-term observation of patients successfully switched to risperidone long-acting injectable: A retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs

Q44288030

Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia

Q45747274

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis

Q46896761

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Q46896771

Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.

Q50719241

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

Q55054009

Effectiveness of switching antipsychotic medications

Q79411250

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

schizophrenia

psychosis

hospitalization

page(s)

917-925

P577

publication date

2013-05-28

P1433

published in

Journal of Medical Economics

Q6295521

P1476

title

Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia

P478

volume

Reverse relations

cites work (P2860)

Q92775984	Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia
Q38223569	Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia
Q34501911	Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil
Q38592404	Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia
Q92776152	Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
Q60919880	Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
Q100565553	Effects of aripiprazole long-acting injectable antipsychotic on hospitalization in recent-onset schizophrenia
Q47958975	Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics
Q90731688	Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
Q89329510	Evaluation of adherence in patients prescribed long-acting injectable antipsychotics: A comparison of biweekly versus monthly administered neuroleptics
Q36550998	Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis
Q35566090	Impact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophrenia
Q90186939	Improving the "real life" management of schizophrenia spectrum disorders by LAI antipsychotics: A one-year mirror-image retrospective study in community mental health services
Q94321436	Long‐acting aripiprazole (depot) versus placebo for schizophrenia
Q64107425	Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study
Q38248274	Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
Q38352080	Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists
Q92236786	Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies
Q37306488	The Cost of Inpatient Care of Schizophrenia and Treatment Schedules Used in German Academic Center: Kiel.
Q34418847	The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.
Q39038512	Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program
Q53654663	[Advantages and controversies of depot antipsychotics in the treatment of patients with schizophrenia].